An interventional study of Tadalafil in Chronic Obstructive Lung Disease, sponsored by Herlev Hospital. Withdrawn at 1 site in Denmark. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-03-18.
Sponsored by Herlev Hospital · Not applicable, Interventional, and Treatment
Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.
Twenty outpatients with Chronic Obstructive Lung Disease (COPD) and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks. Primary effect parameter is 6 min. walking test.
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
Browse Lung Diseases studies →Herlev Hospital is the lead sponsor of 195 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Drug: Tadalafil
40 mg tablet
Also known as: PDE5 inhibitor
Change in 6 min. walking test
Time frame: 6 months
This study is withdrawn, as verified in Jul 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Herlev Hospital